Skip to main content
SpringerLink
Log in

Letter From the Commissioner’s Office at the US FDA

  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Philipson TJ, Berndt ER, Gottschalk A, et al. Assessing the safety and efficacy of the FDA: the case of the Prescription Drug User Fee Acts (NBER working paper w11724, 2005). Cambridge (MA): National Bureau of Economic Research, 2005 [online]. Available from URL: http://www.nber.org/pa pers [Accessed 2006 Nov 20]

    Google Scholar 

  2. Begosh A, Goldsmith J, Hass E, et al. Black box warnings and drug safety: examining the determinants and timing of FDA warning labels (NBER working paper, in press). Cambridge (MA): National Bureau of Economic Research

  3. Vernon JA, Golec JH, Lutter RW, et al. FDA new drug approval times, prescription drug user fees, and R & D spending (AEI-Brookings Joint Center for Regulatory Studies working paper 06-21; 2006) [online]. Available from URL: http://ww w.aei.brookings.org/publications [Accessed 2006 Nov 2]

Download references

Author information

Authors and Affiliations

  1. Senior Economic Policy Advisor, Office of the Commissioner, US Food and Drug Administration, Rockville, Maryland, USA

    John A. Vernon

Authors
  1. John A. Vernon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vernon, J.A. Letter From the Commissioner’s Office at the US FDA. Pharmacoeconomics 25, 1–2 (2007). https://doi.org/10.2165/00019053-200725010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200725010-00001

Search

Navigation